Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model.

Quinn TJ, Yuan Z, Adem A, Geha R, Vrikshajanani C, Koba W, Fine E, Hughes DT, Schmid HA, Libutti SK.

Surgery. 2012 Dec;152(6):1068-77. doi: 10.1016/j.surg.2012.08.021. Epub 2012 Oct 24.

2.

Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression.

Walls GV, Stevenson M, Soukup BS, Lines KE, Grossman AB, Schmid HA, Thakker RV.

Endocrinology. 2016 May;157(5):1789-98. doi: 10.1210/en.2015-1965. Epub 2016 Mar 18.

3.

Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.

Faggiano A, Tavares LB, Tauchmanova L, Milone F, Mansueto G, Ramundo V, De Caro ML, Lombardi G, De Rosa G, Colao A.

Clin Endocrinol (Oxf). 2008 Nov;69(5):756-62. doi: 10.1111/j.1365-2265.2008.03301.x. Epub 2008 May 14.

PMID:
18485119
4.

Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas.

Marciello F, Di Somma C, Del Prete M, Marotta V, Ramundo V, Carratù A, de Luca di Roseto C, Camera L, Colao A, Faggiano A.

Endocrine. 2014 Aug;46(3):678-81. doi: 10.1007/s12020-013-0145-2. Epub 2014 Jan 3.

PMID:
24385268
5.
6.

Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours.

Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, De Luca L, Circelli L, Colantuoni V, Di Sarno A, Carratù AC, de Luca di Roseto C, Colao A, Faggiano A; Multidisciplinary Group for Neuroendocrine Tumors of Naples.

Clin Endocrinol (Oxf). 2014 Jun;80(6):850-5. doi: 10.1111/cen.12411. Epub 2014 Feb 19.

PMID:
24443791
7.

Proliferation rates of multiple endocrine neoplasia type 1 (MEN1)-associated tumors.

Walls GV, Reed AA, Jeyabalan J, Javid M, Hill NR, Harding B, Thakker RV.

Endocrinology. 2012 Nov;153(11):5167-79. doi: 10.1210/en.2012-1675. Epub 2012 Sep 28.

8.

EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1.

van Asselt SJ, Brouwers AH, van Dullemen HM, van der Jagt EJ, Bongaerts AH, Kema IP, Koopmans KP, Valk GD, Timmers HJ, de Herder WW, Feelders RA, Fockens P, Sluiter WJ, de Vries EG, Links TP.

Gastrointest Endosc. 2015 Jan;81(1):159-167.e2. doi: 10.1016/j.gie.2014.09.037.

PMID:
25527055
9.

Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life.

Gonçalves TD, Toledo RA, Sekiya T, Matuguma SE, Maluf Filho F, Rocha MS, Siqueira SA, Glezer A, Bronstein MD, Pereira MA, Jureidini R, Bacchella T, Machado MC, Toledo SP, Lourenço DM Jr.

J Clin Endocrinol Metab. 2014 Jan;99(1):E89-96. doi: 10.1210/jc.2013-1768. Epub 2013 Dec 20.

PMID:
24178797
10.

The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.

van der Hoek J, van der Lelij AJ, Feelders RA, de Herder WW, Uitterlinden P, Poon KW, Boerlin V, Lewis I, Krahnke T, Hofland LJ, Lamberts SW.

Clin Endocrinol (Oxf). 2005 Aug;63(2):176-84.

PMID:
16060911
11.

Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study.

Kann PH, Balakina E, Ivan D, Bartsch DK, Meyer S, Klose KJ, Behr T, Langer P.

Endocr Relat Cancer. 2006 Dec;13(4):1195-202.

12.

In vivo proton MR spectroscopy of pancreatic neuroendocrine tumors in a multiple endocrine neoplasia type 1 conditional knockout mouse model.

Cui MH, Branch CA, Cahill SM, Quinn TJ, Adem A, Libutti SK, Yuan Z.

Magn Reson Med. 2015 Nov;74(5):1221-6. doi: 10.1002/mrm.25529. Epub 2014 Nov 13.

13.

Pancreatic neuroendocrine neoplasms.

Hörsch D, Bert T, Schrader J, Hommann M, Kaemmerer D, Petrovitch A, Zaknun J, Baum RP.

Minerva Gastroenterol Dietol. 2012 Dec;58(4):401-26. Review.

PMID:
23207615
14.

Targeting β-catenin signaling for therapeutic intervention in MEN1-deficient pancreatic neuroendocrine tumours.

Jiang X, Cao Y, Li F, Su Y, Li Y, Peng Y, Cheng Y, Zhang C, Wang W, Ning G.

Nat Commun. 2014 Dec 17;5:5809. doi: 10.1038/ncomms6809.

15.

Multiple effects of somatostatin analogs verified in three cases of metastasized neuroendocrine tumors of the gastroenteropancreatic system.

Biliotti G, Martini F, Vaggelli L, Messerini L, Colagrande S, Pupi A, Seghi P.

Tumori. 2006 Mar-Apr;92(2):170-4.

PMID:
16724698
16.

Pasireotide for malignant insulinoma.

Tirosh A, Stemmer SM, Solomonov E, Elnekave E, Saeger W, Ravkin Y, Nir K, Talmor Y, Shimon I.

Hormones (Athens). 2016 Apr;15(2):271-6. doi: 10.14310/horm.2002.1639.

17.

Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.

Oberg K.

Expert Rev Anticancer Ther. 2009 May;9(5):557-66. doi: 10.1586/era.09.26. Review.

PMID:
19445573
18.

Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.

Petersenn S, Bollerslev J, Arafat AM, Schopohl J, Serri O, Katznelson L, Lasher J, Hughes G, Hu K, Shen G, Reséndiz KH, Giannone V, Beckers A.

J Clin Pharmacol. 2014 Nov;54(11):1308-17. doi: 10.1002/jcph.326. Epub 2014 May 24.

PMID:
24800725
19.

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.

Kvols LK, Oberg KE, O'Dorisio TM, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L, Wiedenmann B.

Endocr Relat Cancer. 2012 Sep 14;19(5):657-66. doi: 10.1530/ERC-11-0367. Print 2012 Oct.

20.

Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs.

Imam H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E, Oberg K.

Acta Oncol. 1997;36(6):607-14.

PMID:
9408151

Supplemental Content

Support Center